Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis
- Design
- Meta-analysis · 3459 participants · Intermediate outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all included trials enrolled obese adults, with or without diabetes.
- Could weight loss explain it?
- Not applicableOutcomes are weight, BMI and HbA1c themselves; weight mediation is not a meaningful question for them.
- Study tier
- Study tier 2MODERATE: meta-analysis of randomized trials (3459 participants) with intermediate outcomes; fixed-effects pooling and no confidence intervals in the abstract; the comparison is 36 mg against 12 mg, not against placebo.
- Assessment
- Version 3 · Two independent AI reviews agreed · Nov 7, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
Six randomized trials with 3459 adults with obesity, with or without diabetes, were pooled in this meta-analysis comparing two maintenance doses of the oral GLP-1 drug orforglipron. The 36 mg dose produced greater reductions in body weight, BMI, HbA1c, waist size, triglycerides and systolic blood pressure than 12 mg. Side effects were similar overall, though liver enzymes (ALT and AST) rose slightly on the higher dose and the trials could not detect rare or long-term harms.
01Findings
What the study reported
- Drugs
- Orforglipron
- Dose
- 12 mg vs. 36 mg
- Route
- oral
- Comparator
- orforglipron 12 mg (lower maintenance dose)
- Primary outcome
- percentage and absolute body weight change (plus BMI, HbA1c, waist, lipids, blood pressure, adverse events)
- Effect
- 36 mg vs 12 mg: greater reductions in percentage body weight change (p < 0.00001), absolute body weight, BMI, HbA1c, waist circumference (all p < 0.00001), triglycerides (P = 0.002) and systolic blood pressure (P = 0.002); adverse events comparable; no significant differences in GI events or pancreatic function
- 95% confidence interval
- Not extracted
- P value
- p < 0.00001 (percentage body weight change)
- Follow-up
- Not stated
- Adverse events
- Adverse events comparable between doses; no significant differences in GI events or pancreatic function; small pulse-rate difference; small ALT and AST increases with 36 mg; trials not powered for rare or long-term events
- Limitations
- Dose-comparison meta-analysis of six trials using a fixed-effects model with no confidence intervals in the abstract; the authors note the trials were not powered for rare or long-term adverse events and longer studies are needed.
Who was studied
- Obesity status
- required (obese adults; no BMI criterion stated)
- Diabetes status
- mixed (with or without diabetes)
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- obesity
- Sample size
- 3459
- Inclusion exclusion
- RCTs comparing orforglipron 12 mg and 36 mg in obese adults
Study quality details
- Study design
- Meta-analysis
- Sample size
- 3459
- Randomization
- yes
- Blinding
- not stated
- Comparator
- orforglipron 12 mg (lower maintenance dose)
- Follow up duration
- not stated
- Outcome type
- intermediate
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no CI reported; p values only; 3459 participants in 6 RCTs
- Risk of bias
- not assessed
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- Authors declare no conflicts
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[BACKGROUND] Obesity is projected to affect about one billion adults by 2030 and is associated with cardiometabolic morbidity. Orforglipron is an oral, non-peptide glucagon-like peptide-1 receptor agonist developed to provide weight and metabolic benefits. Prior meta-analyses have supported its efficacy and safety but were limited by shorter follow-up and a predominance of non-diabetic populations. This meta-analysis aims to provide the most comprehensive head-to-head comparison between the two most commonly studied maintenance doses (12 mg vs. 36 mg), assessing weight, glycemic, cardiometabolic, and safety outcomes. [METHODS] We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults. Outcomes of interest included percentage and absolute body weight change, BMI, HbA1c, waist circumference, lipid parameters, blood pressure, and adverse events. Results were pooled using a fixed-effects model, and prespecified subgroup analyses examined differences by diabetes status and treatment duration. [RESULTS] Six RCTs (3459 participants) were included. Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in percentage body weight change (p < 0.00001), absolute body weight change (p < 0.00001), body mass index (p < 0.00001), HbA1c (p < 0.00001), waist circumference (P < 0.00001), percent change in triglycerides (P = 0.002), and systolic blood pressure (P = 0.002). Adverse events were comparable between doses. No significant differences were observed in gastrointestinal events or pancreatic functions. A small difference in pulse rate was noted but was not considered clinically significant. [CONCLUSION] In obese adults, orforglipron 36 mg improved weight and metabolic outcomes compared with 12 mg. No statistically significant differences between doses were detected for the prespecified safety outcomes, although small increases in ALT and AST were observed with the 36 mg dose and the trials included were not powered to detect rare or long-term adverse events. These findings support consideration of the higher maintenance dose when clinically appropriate. Longer-term studies are needed to confirm the benefit and cardiovascular outcomes. [CLINICAL TRIAL NUMBER] Not applicable.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 20, 2026 | 42750018 first ingestion |
| pubmed | Sep 20, 2026 | 42750018 duplicate matched on doi |
| pubmed | Sep 20, 2026 | 42750018 duplicate matched on doi |
| pubmed | Sep 27, 2026 | 42750018 duplicate matched on doi |
| pubmed | Sep 27, 2026 | 42750018 duplicate matched on doi |
| pubmed | Sep 27, 2026 | 42750018 duplicate matched on doi |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |
| reextract | Nov 6, 2026 | dose: '12 mg' -> '12 mg, 36 mg'. Q-043: manufacturer and drug_details.dose re-extracted by auto-classifier-v1.2. manufacturer no longer reads companies named only in the authors' conflicts statement (IN-062) and refuses a multi-company roster; dose is tied to the GLP-1 agent by name, never reads a concentration, and records a multi-dose design whole. Every other value is carried forward unchanged. Owner decision IN-064 option 1, 2026-11-06. |